Sridharan K, Sivaramakrishnan G
BMC Cardiovasc Disord. 2025; 25(1):180.
PMID: 40087557
DOI: 10.1186/s12872-025-04510-4.
Sridharan K, Sivaramakrishnan G
BDJ Open. 2025; 11(1):24.
PMID: 40069171
PMC: 11897221.
DOI: 10.1038/s41405-024-00291-8.
Chretien B, Rabiaza A, Kazuki N, Fedrizzi S, Sassier M, Dolladille C
PLoS One. 2025; 20(3):e0317841.
PMID: 40053562
PMC: 11888134.
DOI: 10.1371/journal.pone.0317841.
Saint-Lary L, Beau A, Sommet A, Leroy V, Loane M, Cavero-Carbonell C
Eur J Clin Pharmacol. 2025; .
PMID: 40011239
DOI: 10.1007/s00228-025-03814-w.
Sridharan K, Sivaramakrishnan G
J Clin Med. 2025; 14(4).
PMID: 40004629
PMC: 11856106.
DOI: 10.3390/jcm14041097.
Are Causal Statements Reported in Pharmacovigilance Disproportionality Analyses Using Individual Case Safety Reports Exaggerated in Related Citations? A Meta-epidemiological Study.
Bernardeau C, Revol B, Salvo F, Fusaroli M, Raschi E, Cracowski J
Drug Saf. 2025; .
PMID: 39987376
DOI: 10.1007/s40264-025-01524-x.
Dementia and Alzheimer's Disease Associated With Aromatase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase).
Yuste M, Sainz-Gil M, Escudero E, Marin P
Pharmacol Res Perspect. 2025; 13(1):e70075.
PMID: 39917951
PMC: 11803411.
DOI: 10.1002/prp2.70075.
PDL1 inhibitors may be associated with a lower risk of allograft rejection than PD1 and CTLA4 inhibitors: analysis of the WHO pharmacovigilance database.
Gerard A, Merino D, Benzaquen J, Destere A, Borchiellini D, Gosset C
Front Immunol. 2025; 16:1514033.
PMID: 39911399
PMC: 11794220.
DOI: 10.3389/fimmu.2025.1514033.
Birth defects reporting and the use of dydrogesterone: a disproportionality analysis from the World Health Organization pharmacovigilance database (VigiBase).
Henry A, Santulli P, Bourdon M, Maignien C, Chapron C, Treluyer J
Hum Reprod Open. 2025; 2025(1):hoae072.
PMID: 39807112
PMC: 11726828.
DOI: 10.1093/hropen/hoae072.
Interaction between dipeptidyl-peptidase-4 inhibitors and drugs acting on renin angiotensin aldosterone system for the risk of angioedema: a pharmacovigilance assessment using disproportionality and interaction analyses.
Sridharan K, Sivaramakrishnan G
Diabetol Metab Syndr. 2025; 17(1):7.
PMID: 39773243
PMC: 11706060.
DOI: 10.1186/s13098-024-01570-y.
Systemic adverse drug events to topical prostaglandin analogs for treating glaucoma: a retrospective focused pharmacovigilance study.
Sridharan K
BMC Ophthalmol. 2024; 24(1):554.
PMID: 39741235
PMC: 11686995.
DOI: 10.1186/s12886-024-03823-w.
Exploring Human Misuse and Abuse of Veterinary Drugs: A Descriptive Pharmacovigilance Analysis Utilising the Food and Drug Administration's Adverse Events Reporting System (FAERS).
Dunn J, Schifano F, Dudley E, Guirguis A
Toxics. 2024; 12(11).
PMID: 39590957
PMC: 11597946.
DOI: 10.3390/toxics12110777.
Characteristics of adverse reactions of three anti-glioma drugs in WHO-VigiAccess.
Ke H, Zhang Z, Yu Z, Zhang B, Chen R, Zhou Q
Front Pharmacol. 2024; 15:1485067.
PMID: 39512822
PMC: 11540626.
DOI: 10.3389/fphar.2024.1485067.
Evaluation of tolvaptan-associated hepatic disorder using different national pharmacovigilance databases.
Uno T, Hosomi K, Yokoyama S
Sci Rep. 2024; 14(1):25943.
PMID: 39472632
PMC: 11522566.
DOI: 10.1038/s41598-024-77052-y.
Hepatotoxicity of antipsychotics: an exploratory pharmacoepidemiologic and pharmacodynamic study integrating FAERS data and receptor-binding affinities.
Zeiss R, Schonfeldt-Lecuona C, Connemann B, Hafner S, Gahr M
Front Psychiatry. 2024; 15:1479625.
PMID: 39469476
PMC: 11513306.
DOI: 10.3389/fpsyt.2024.1479625.
Lipschütz ulcer following first dose of COVID-19 tozinameran vaccine: Report of a case and review of a World Health Organization pharmacovigilance database.
Ewig E, Ben Othman N, Viard D, Gauci P, Rocher F, Drici M
Int J Gynaecol Obstet. 2024; 168(3):958-964.
PMID: 39441542
PMC: 11823353.
DOI: 10.1002/ijgo.15941.
Adverse Event Profile of First-line Drugs for Treating Patent Ductus Arteriosus in Neonates: A Disproportionality Analysis Study of USFDA Adverse Event Reporting System.
Sridharan K, Sivaramakrishnan G
Paediatr Drugs. 2024; 26(6):767-785.
PMID: 39367998
DOI: 10.1007/s40272-024-00657-3.
GLP 1 receptor agonists and obesity-associated cancers: a disproportionality analysis in Vigibase®.
Montastruc J
Eur J Clin Pharmacol. 2024; 80(12):1999-2001.
PMID: 39331139
DOI: 10.1007/s00228-024-03761-y.
An Integrated Approach for Representing Knowledge on the Potential of Drugs to Cause Acute Kidney Injury.
Fernandez-Llaneza D, Vos R, Lieverse J, Gosselt H, Kane-Gill S, van Gelder T
Drug Saf. 2024; 48(1):43-58.
PMID: 39327387
PMC: 11711143.
DOI: 10.1007/s40264-024-01474-w.
Tumor lysis syndrome signal with the combination of encorafenib and binimetinib for malignant melanoma: a pharmacovigilance study using data from the FAERS database.
Xia S, Xu J, Yan K, Noguchi Y, Sarangdhar M, Yan M
Front Pharmacol. 2024; 15:1413154.
PMID: 39314755
PMC: 11417307.
DOI: 10.3389/fphar.2024.1413154.